Anti-inflammatory lipid mediators and insights into the resolution of inflammation

Nature Reviews Immunology

Volumn 2, Issue 10, 2002, Pages 787-795

  Lawrence, Toby ^a,b   Willoughby, Derek A ^b   Gilroy, Derek W ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ALPHA5 INTEGRIN; BETA3 INTEGRIN; CYCLIC AMP; CYCLOPENTENONE DERIVATIVE; CYCLOPENTENONE PROSTAGLANDIN; GLUCOCORTICOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; LIPOXIN; NORADRENALIN; PHOSPHATIDYLSERINE; PROSTAGLANDIN; PROSTAGLANDIN G1; PROSTAGLANDIN G2; PROSTAGLANDIN J2; THROMBOSPONDIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; AUTACOID; LIPID;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; CELL KINETICS; CELL TRANSPORT; DNA BINDING; GENE EXPRESSION; LEUKOCYTE ACTIVATION; LEUKOCYTE MIGRATION; MEDIATOR RELEASE; MICROCIRCULATION; MOLECULAR CLONING; MOLECULAR DYNAMICS; MOLECULAR MECHANICS; PHAGOCYTOSIS; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; BIOLOGICAL MODEL; HUMAN; IMMUNOLOGY; INFLAMMATION; PATHOPHYSIOLOGY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; APOPTOSIS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; LIPIDS; MODELS, IMMUNOLOGICAL; NF-KAPPA B; PHAGOCYTOSIS; SIGNAL TRANSDUCTION;

EID: 0036779617     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri915     Document Type: Review

References (63)

1. Florey, H. W. General Pathology (Lloyd-Luke, London, 1970).
2. Majno, G. The Healing Hand: Man and Wound in the Ancient World (Harvard University Press, Cambridge, Massachusetts, 1975). These two historical references give an excellent account of the experimental pathology of inflammation and highlight aspects that are generally ignored in more recent texts that focus on molecular events.
3. Jay, S. J., Johanson, W. G. Jr & Pierce, A. K. The radiographic resolution of Streptococcus pneumoniae pneumonia. N. Engl. J. Med. 293, 798-801 (1975).
4. Deepe, G. S. Jr & Eagleton, L. E. Resolution of influenzal pneumonia. IMJ III. Med. J. 158, 76-78 (1980).
5. Metlay, J. P., Atlas, S. J., Borowsky, L. H. & Singer, D. E, Time course of symptom resolution in patients with community-acquired pneumonia. Respir. Med. 92, 1137-1142 (1998).
6. Larsen, G. L. & Henson, P. M. Mediators of inflammation. Annu. Rev. Immunol. 1, 335-359 (1983).
7. Shanley, T. P., Warner, R. L. & Ward, P. A. The role of cytokines and adhesion molecules in the development of inflammatory injury. Mol. Med. Today 1, 40-45 (1995).
8. Spector, W. G. & Willoughby, D. A. Local treatment of experimental burns with a monoamine oxidase inhibitor. Nature 189, 489-490 (1961).
9. Spector, W. G., Walters, M. & Willoughby, D. A. Venular and capillary permeability in thermal injury. J. Path. Bacteriol. 90, 635-640 (1965).
10. Spector, W. G. & Willoughby, D. A. Suppression of increased capillary permeability in injury by monoamine oxidase inhibitors. Nature 186, 162-163 (1960).
11. Ottonello, L., Morone, M. P., Dapino, P. & Dallegri, F. Cyclic AMP-elevating agents down-regulate the oxidative burst induced by granulocyte-macrophage colony-stimulating factor (GM-CSF) in adherent neutrophils. Clin. Exp. Immunol. 101, 502-506 (1995).
12. Moore, A. R. & Willoughby, D. A. The role of cAMP regulation in controlling inflammation. Clin. Exp. Immunol. 101, 387-389 (1995).
13. Adcock, I. M. Molecular mechanisms of glucocorticoids actions. Pulm. Pharmacol. Ther. 13, 115-126 (2000).
14. Goulding, N. J. et al. Anti-inflammatory lipocortin 1 production by peripheral-blood leucocytes in response to hydrocortisone. Lancet 335, 1416-1418 (1990).
15. Cinno, G. & Flower, R. J. Human recombinant lipocortin 1 inhibits prostacyclin production by human umbilical artery in vitro. Prostaglandins 34, 59-62 (1987).
16. Perretti, M. & Flower, R. J. Modulation of IL-1-induced neutrophil migration by dexamethasone and lipocortin 1. J. Immunol. 150, 992-999 (1993)
17. Serhan, C. N. Lipoxin biosynthesis and its impact in inflammatory and vascular events. Biochim. Biophys. Acta 1212, 1-25 (1994).
18. Soyombo, O., Spur, B. W. & Lee, T. H. Effects of lipoxin A4 on chemotaxis and degranulation of human eosinophils stimulated by platelet-activating factor and N-formyl-L-methionyl-L-leucyl-L-phenylalanine. Allergy 49, 230-234 (1994).
19. Maddox, J. F. et al. Lipoxin B4 regulates human monocyte/neutrophil adherence and motility: design of stable lipoxin B4 analogs with increased biologic activity. FASEB J. 12, 487-494 (1998).
20. Colgan, S. P., Serhan, C. N., Parkos, C. A., Delp-Archer, C. & Madara, J. L. Lipoxin A4 modulates transmigration of human neutrophils across intestinal epithelial monolayers. J. Clin. Invest. 92, 75-82 (1993).
21. Raud, J., Palmertz, U., Dahlen, S. E. & Hedqvist, R. Lipoxins inhibit microvascular inflammatory actions of leukotriene B4. Adv. Exp. Med. Biol. 314, 185-192 (1991).
22. Maddox, J. F. & Serhan, C. N. Lipoxin A4 and B4 are potent stimuli for human monocyte migration and adhesion: selective inactivation by dehydrogenation and reduction. J. Exp. Med. 183, 137-146 (1996).
23. Godson, C. et al. Cutting edge: lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages. J. Immunol. 164, 1663-1667 (2000).
24. 2 is an endogenous antiinflammatory mediator in vivo.
25. Bandeira-Melo, C. et al. Cyclooxygenase-2-derived prostaglandin E2 and lipoxin A4 accelerate resolution of allergic oedema in Angiostrongylus costaricensis-infected rats: relationship with concurrent eosinophilia. J. Immunol. 164, 1029-1036 (2000).
26. Ianaro, A., Ialenti, A., Maffia, P., Pisano, B. & Di Rosa, M. Role of cyclopentenone prostaglandins in rat carrageenin pleurisy. FEBS Lett. 508, 61-66 (2001).
27. Levy, B. D., Clish, C. B., Schmidt, B., Gronert, K. & Serhan, C. N. Lipid mediator class switching during acute inflammation: signals in resolution. Nature Immunol. 2, 612-619 (2001).
28. 2 induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats. J. Clin. Invest. 106, 189-197 (2000).
29. 2 ameliorates experimental autoimmune encephalomyelitis. J. Immunol. 168, 2608-2615 (2002).
30. Clark, R. B. et al. The nuclear receptor PPARγ and Immunoregulation: PPARγ mediates inhibition of helper T-cell responses. J. Immunol. 164, 1364-1371 (2000).
31. 2 and proliferator activation receptor-γ agonists. J. Immunol. 164, 1498-1504 (2000).
32. Combs, C K., Johnson, D. E., Karlo, J. C., Cannady, S. B. & Landreth, G. E. Inflammatory mechanisms in Alzheimer's disease: inhibition of β-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARγ agonists. J. Neurosci. 20, 558-567 (2000).
33. Pasceri, V., Wu, H. D., Willerson, J. T. & Yeh, E. T. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-γ activators. Circulation 101, 235-238 (2000).
34. Jackson, S. M. et al. Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leucocyte-endothelial-cell interaction. Arterioscler. Thromb. Vasc. Biol. 19, 2094-2104 (1999).
35. 2 integrin-dependent oxidative burst: involvement of a mechanism distinct from peroxisome proliferator-activated receptor-7 ligation. J. Immunol. 163, 6187-6192 (1999).
36. 2. J. Immunol. 166, 7104-7111 (2001).
37. Rossi, A., Elia, G. & Santoro, M. G. Inhibition of nuclear factor κB by prostaglandin A1: an effect associated with heat shock transcription factor activation. Proc. Natl. Acad. Sci. USA 94, 746-750 (1997).
38. Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J. & Glass, C. K. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 391, 79-82 (1998).
39. 2 as a potent modulator of macrophage activation in vitro.
40. Colville-Nash, P. R., Qureshi, S. S., Willis, D. & Willoughby, D. A. Inhibition of inducible nitric oxide synthase by peroxisome proliferator-activated receptor agonists: correlation with induction of heme oxygenase 1. J. Immunol. 161, 978-984 (1998).
41. 2 in activated murine macrophages. Mol. Cell. Biol. 20, 1692-1698 (2000).
42. 2 inhibits multiple steps in the NF-κB signaling pathway. Proc. Natl Acad. Sci. USA 97, 4844-4849 (2000).
43. Haslett, C. Granulocyte apoptosis and its role in the resolution and control of lung inflammation. Am. J. Respir. Crit. Care Med. 160, S5-S11 (1999). An excellent review of the role of granulocyte apoptosis in the resolution of inflammation.
44. Savill, J. & Fadok, V. Corpse clearance defines the meaning of cell death. Nature 407, 784-788 (2000). This review describes how the recognition and phagocytosis of apoptotic cells might regulate the inflammatory response.
45. Lawrence, T., Gilroy, D. W., Colville-Nash, P. R. & Willoughby, D. A. Possible new role for NF-κB in the resolution of inflammation. Nature Med. 7, 1291-1297 (2001).
46. 2. J. Biol. Chem. 214, 17042-17048 (1999).
47. + lymphocytes. J. Immunol. 165, 1743-1754 (2000).
48. 2 and its metabolites induce caspase-dependent granulocyte apoptosis that is mediated via inhibition of IκBα degradation using a peroxisome proliferator-activated receptor-γ-independent mechanism. J. Immunol. 168, 6232-6243 (2002).
49. 2 and PAF. J. Clin. Invest. 101, 890-898 (1998).
50. Huynh, M. L., Fadok, V. A. & Henson, P. M. Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-β1 secretion and the resolution of inflammation. J. Clin. Invest. 109, 41-50 (2002).
51. van Lent, P. L. et al. Uptake of apoptotic leucocytes by synovial lining macrophages inhibits immune complex-mediated arthritis. J. Leukocyte Biol. 70, 708-714 (2001).
52. Dibbert, B. et al. Cytokine-mediated Bax deficiency and consequent delayed neutrophil apoptosis: a general mechanism to accumulate effector cells in inflammation. Proc. Natl Acad. Sci. USA 96, 13330-13335 (1999). This paper presents evidence for defects in apoptosis in clinical samples from patients with inflammatory lung disease.
53. Vandivier, R. W. et al. Elastase-mediated phosphatidylserine receptor cleavage impairs apoptotic-cell clearance in cystic fibrosis and bronchiectasis. J. Clin. Invest. 109, 661-670 (2002).
54. Taylor, P. R. et al. A hierarchical role for classical-pathway complement proteins in the clearance of apoptotic cells in vivo. J. Exp. Med. 192, 359-366 (2000).
55. Straus, D. S. & Glass, C. K. Cyclopentenone prostaglandins: new insights on biological activities and cellular targets. Med. Res. Rev. 21, 185-210 (2001).
56. Clark, R. B. The role of PPARs in inflammation and immunity. J. Leukocyte Biol. 71, 388-400 (2002).
57. 2.
58. 2 inhibition of NF-κB-DNA binding through covalent modification of the p50 subunit. J. Biol. Chem. 276, 35530-35536 (2001).
59. Karin, M. & Ben-Neriah, Y. Phosphorylation meets ubiquitination: the control of NF-κB activity. Annu. Rev. Immunol. 18, 621-663 (2000).
60. Ward, C. et al. NF-κB activation is a critical regulator of human granulocyte apoptosis in vitro. J. Biol. Chem. 274, 4309-4318 (1999).
61. Fierro, I. M. & Serhan, C. N. Mechanisms in anti-inflammation and resolution: the role of lipoxins and aspirin-triggered lipoxins. Braz. J. Med. Biol. Res. 34, 555-566 (2001).
62. 4. Nature Med. 8, 1018-1023 (2002).
63. 2 metabolite generated during inflammatory processes. J. Biol. Chem. 277, 10459-10466 (2002).